ArticleLeukemia2019

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Tania Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.